Today I am thrilled to announce the launch of our next landmark research investment, PASS-01: a clinical trial that will finally address the diverse nature of this disease and provide personalized treatment options for advanced pancreatic cancer patients.For over 40 years there has been a"one size fits all" approach to pancreatic cancer treatment that has kept the survival rate in the single digits. The lack of effective treatment optionshas been a devastating realityfor all patients, but especially for the roughly 80%diagnosed with inoperable pancreatic cancer. When I talk to these patients and their loved ones I hear one thing consistently: they want more time.Led by women scientists at the top of their field, PASS-01 is a collaborative effortthatdrawson the expertise ofthe most prestigious cancer research centres in Canada and the US to advance personalized medicine for pancreatic cancer patients. Using next-generation organoid technology, researchers will be able to efficiently test multiple treatments on a patient's cancer cells to see which treatment would be most effective, ultimately giving patients the best chance at a longer life.PASS-01 is yetanother example of the impact of Pancreatic Cancer Canada'spast research investments. By studying potential biomarkers and disease subtypes identified bythe ground-breaking COMPASS trial, PASS-01 is poised to succeed where other trials have failed, basing treatment decisions on the nuanced genomic information that varies from patient to patient.PASS-01 is the second clinical trial Pancreatic Cancer Canada has launched in the last year - all in the middle of a global pandemic - because pancreatic cancer patients do not have time to wait. I invite you to learn more about PASS-01andconsider making a donation today. With your help we will raise the rate of pancreatic cancer survival.To read the full press release click here.Sincerely,